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Introduction
============

Standard treatment for glioblastoma (GBM) in patients younger than 65--70 years involves maximal surgical resection plus radical long-course chemoradiotherapy, followed by adjuvant chemotherapy with temozolomide \[[@REF1]\]. Despite aggressive multimodality therapy, prognosis remains poor, with a median overall survival of 14.6 months, and two-year overall survival of 27%.

Tumor-like stem cells (TLSC) exhibit properties that help maintain and promote tumor growth \[[@REF2],[@REF3]\]. TLSC have been isolated and extensively studied in GBM \[[@REF2]-[@REF5]\]. Research suggests they may contribute to negative outcomes associated with this disease. In both cultured cells and mice models, neural stem cells (NSC) and TLSC both express CD133, which is correlated with greater radioresistance, repopulation, and DNA damage checkpoint response \[[@REF6]\]. Disrupted K-ras signaling, a biologic regulator of NSC, has been shown to induce gliomatosis \[[@REF7]\]. Mutations in epidermal growth factor receptor (EGFR) have also been encountered in glioma, and in NSC, confer a proliferative advantage and enhanced tumor cell survival \[[@REF8]\]. One well-characterized reservoir of NSC in humans is the subventricular zone (SVZ) \[[@REF9]-[@REF12]\]. In some studies, tumor proximity or involvement of the SVZ has been related to poorer prognosis \[[@REF13]-[@REF15]\].

In recent years, there has been speculation as to whether irradiation of NSCs in the SVZ may improve outcome. Unfortunately, there is limited data on the impact of dose to the  SVZ, which consists of mostly small, retrospective studies with conflicting results \[[@REF16]-[@REF26]\]. Some of these studies suggest that higher dose to the SVZ is associated with better outcome, raising the possibility that targeted inclusion of this area into the treatment volume may improve survival \[[@REF20], [@REF22]-[@REF26]\]. The largest of these studies assessed 173 subjects, and found that a higher ipsilateral SVZ dose correlated with better progression-free survival (PFS) and overall survival (OS) \[[@REF25]\]. The next largest study involved 116 subjects, but found a benefit only within patients who underwent gross total resection (GTR) \[[@REF26]\]. The SVZ is anatomically close to the hippocampal formation, and since irradiation of this region is potentially toxic \[[@REF27],[@REF28]\], a clearer understanding of the potential benefit of targeting the SVZ is warranted. This study investigates whether SVZ dose is correlated with survival outcomes in a large cohort of GBM patients treated with radical long-course CRT and concomitant temozolomide.

Materials and methods
=====================

Patients

The patients in this study received treatment at an institution that provides all radiotherapy services provincially. This study was approved by the institutional research ethics board. Between 2006 and 2012, all patients above age 18 with pathologically proven GBM treated at the institution with long-course CRT, who completed the full course of radiotherapy and at least 50% of the concurrent chemotherapy, were retrospectively reviewed (n = 370). This study period was chosen to allow sufficient follow-up time (minimum one year) to observe the primary endpoint of PFS. All had initial surgery with GTR, subtotal resection (STR), or biopsy, which was followed by adjuvant radiation (60 Gy in 30 fractions, intensity modulated radiotherapy (IMRT) or 3D-CRT) and at least 50% of the prescribed concomitant temozolomide. Patients were excluded if they did not complete CRT, if full dosimetry data was unavailable, or if the intended final dose was less than 59.4 Gy.

Data collection

Clinical data was extracted from an integrated electronic charting system. SVZs were retrospectively contoured on patients' planning CT scans, in accordance with operational definitions outlined in previous protocols \[[@REF23],[@REF24]\] as 5 mm along the lateral wall of the lateral ventricles for all treatment plans, with the use of co-registered magnetic resonance imaging (MRI) where available. This was done by two radiation therapists and one radiation oncology resident with training in SVZ contouring, and reviewed by a radiation oncologist specializing in central nervous system tumors. Dosimetry was analyzed with the analytical anisotropic algorithm on the Eclipse Planning System (Varian, version 11). Dose-volume histogram (DVH) data was collected for the ipsilateral, contralateral, and bilateral SVZ.

Statistical analysis

Statistical analysis was completed with R Version 3.2.5 (R Foundation, Vienna). The primary endpoints were PFS, defined as the time from histologic confirmation of GBM until radiologic evidence of disease progression and a change in patient management, and OS, until death. Kaplan-Meier (KM) curves of PFS and OS were constructed, comparing patients by dose to ipsilateral, contralateral, and bilateral SVZ. Known prognostic factors were also evaluated. KM curves were compared using the log-rank statistic, two-tailed, with P ≤ 0.05 denoting significance. For PFS, patients were censored at the time of last imaging showing stability if they had not progressed at the time of analysis. For OS, patients were censored at their last follow-up appointment or clinical investigation.

For univariate analysis of prognostic factors, patients were grouped by age (\<50 vs. \>50), tumor location (frontal, temporal, parietal, occipital, cerebellar, butterfly, other), Karnofsky performance status (KPS, \>70, \<70), multifocality, resection (GTR, STR, biopsy), completion of concurrent chemotherapy, completion of adjuvant chemotherapy (\>26, \<26 weeks), type of progression (local, distant, both), and time from diagnosis to CRT (\<median, \>median). The selected cut off for age has been used in similar studies of SVZ irradiation \[[@REF23], [@REF25]\]. SVZ dosimetric data was evaluated for groups defined by cut-off points that included median dose, 40 Gy, and 59.4 Gy. The 40 Gy threshold was selected because SVZ doses in the range of 30--43 Gy have been suggested to be of prognostic significance \[[@REF24], [@REF26]\]. The 59.4 Gy threshold was evaluated due to the postulated radio-resistance of NSCs \[[@REF25]\].

Multivariate Cox proportional hazards (CPH) analysis was performed to identify independent predictors of PFS and OS. Variables included SVZ dose, age at diagnosis, biopsy only, Karnofsky performance status, multifocality, and adjuvant chemotherapy. All covariates, which were known prognostic factors for GBM patient outcome, were included regardless of their significance in the univariate analysis.

Results
=======

Median follow-up time was 16.4 months for the cohort. Three-hundred sixty of the initial 370 patients were included in the analysis. Nine with incomplete dosimetric data, and one with an unconventional radiation prescription (neither 59.4 Gy nor 60 Gy) were excluded. Baseline characteristics of the group are shown in Table [1](#TAB1){ref-type="table"}. Dosimetric data including quartile doses are listed in Table [2](#TAB2){ref-type="table"}. Median PFS for all patients was 8.9 months (95% CI: 8.3--9.8 months), and OS was 16.5 months (95% CI: 15.2--17.6 months).

###### Patient demographics, disease, and treatment characteristics.

MRI: Magnetic resonance imaging; CRT: Chemoradiotherapy; IMRT: Intensity modulated radiotherapy; SD: Standard deviation.

  ----------------------------------- --------- ---------
  Characteristic                      N = 360    
  Sex                                            
     Female                           118       (32.8%)
     Male                             242       (67.2%)
  Age (y)                                        
     \< 50                            83        (23.1%)
     [\>]{.ul} 50                     277       (76.9%)
  Tumor location                                 
     Frontal                          113       (31.4%)
     Temporal                         119       (33.1%)
     Parietal                         84        (23.3%)
     Occipital                        22        (6.1%)
     Butterfly                        16        (4.4%)
     Other                            6         (1.7%)
  Karnofsky performance status                   
     \> 70                            280       (77.8%)
     [\<]{.ul} 70                     80        (22.2%)
  Multifocal                                     
     No                               301       (83.6%)
     Yes                              59        (16.4%)
  MRI size                                       
     \< Median                        180       (50%)
     [\>]{.ul} Median                 180       (50%)
  Resection                                      
     Gross total resection, GTR       173       (48.1%)
     Subtotal resection, STR          135       (37.5%)
     Biopsy                           52        (14.4%)
  Adjuvant chemotherapy completed                
     \>26 Weeks                       176       (48.9%)
     [\<]{.ul} 26 Weeks               184       (51.1%)
  Concurrent chemotherapy completed             
     Yes                              339       (94.2%)
     No                               21        (5.8%)
  Progression type                               
     Local                            257       (71.4%)
     Distant                          11        (3.1%)
     Both                             42        (11.7%)
     No evidence of progression       50        (13.9%)
  RT technique                                   
     3D-CRT                           264       (73.3%)
     IMRT                             95        (26.4%)
     Other                            1         (0.3%)
  Total dose (cGy)                               
     5940                             37        (10.3%)
     6000                             323       (89.7%)
  Time from Dx to RT start (d)                   
     Mean                             41.02      
     SD                               14.27      
  MRI largest dimension (cm)                     
     Mean                             4.43       
     SD                               1.49       
  ----------------------------------- --------- ---------

###### Radiation dosimetric data summary.

SVZ: Subventricular zone

  ------------------------ ------------- --------------- -----------
                           Ipsilateral   Contralateral   Bilateral
  Mean SVZ dose (cGy)                                     
     Mean                  4778          2892            3790
     Median                4900          2806            3780
     1st Quartile          4151          1952            3146
     3rd Quartile          5606          3751            4416
  Minimum SVZ dose (cGy)                                  
     Mean                  1835          908.9           845.1
     Median                1462          524.2           448
     1st Quartile          345           179.6           173.1
     3rd Quartile          2852          1426            1341
  Maximum SVZ dose (cGy)                                  
     Mean                  3158          4846            6158
     Median                6136          5222            6145
     1st Quartile          6070          3851            6073
     3rd Quartile          6250          5974            6254
  ------------------------ ------------- --------------- -----------

On univariate analysis of all patients (Table [3](#TAB3){ref-type="table"}), worse PFS was significantly associated with older age (P = 0.045), lower KPS (P = 0.049), multifocality (P \< 0.001), and failure to complete adjuvant chemotherapy (P \< 0.001). Shorter OS was associated with lower KPS (P = 0.001), biopsy rather than resection (P = 0.003), multifocality (P = 0.009), and failure to complete adjuvant chemotherapy (P \< 0.001). Dose was not significantly associated with either PFS (Figure [1](#FIG1){ref-type="fig"}) or OS, for any of the cut-off points assessed, for ipsilateral, contralateral, and bilateral SVZ, even when analysis was limited to patients who had GTR (Table [3](#TAB3){ref-type="table"}).

###### Univariate analysis of prognostic factors associated with PFS and OS.

PFS: Progression-free survival; OS: Overall survival; SVZ: Subventricular zone; GTR: Gross total resection; STR: Subtotal resection.

  ---------------------------------------- ---------------------------- ----------------- --------- ----------------- ---------
                                                                        PFS               OS                          
  Prognostic Factors                                                    Median (months)   P-value   Median (months)   P-value
  Age                                      \< 50 years                  10.4              0.045     17.8              0.234
                                           [\>]{.ul}50 years            8.7                         16.0               
  Tumor location                           Frontal                      8.8               0.083     17.3              0.057
                                           Temporal                     9.9                         17.0               
                                           Parietal                     8.0                         14.5               
                                           Occipital                    9.6                         17.6               
                                           Butterfly                    11.7                        20.3               
                                           Other                        14.4                        13.6               
  Karnofsky score                          \> 70                        9.7               0.049     17.1              0.001
                                           [\<]{.ul} 70                 7.2                         11.3               
  Multifocality                            No                           9.5               \<0.001   16.8              0.009
                                           Yes                          7.1                         13.7               
  Resection                                GTR                          9.5               0.245     17.2              0.003
                                           STR                          8.8                         17.0               
                                           Biopsy                       6.9                         10.7               
  Adjuvant chemotherapy                    \>26 weeks                   13.6              \<0.001   23.7              \<0.001
                                           [\<]{.ul} 26 weeks           6.2                         10.6               
  Concurrent chemotherapy                  Completed                    9.0               0.535     16.5              0.615
                                           Incomplete                   8.3                         17.8               
  Progression type                         Local                        8.3               0.321     17.0              0.589
                                           Distant                      9.9                         15.0               
                                           Both                         9.8                         12.8               
  Time from diagnosis to RT (median)       \< 39 days                   9.0               0.864     16.5              0.664
                                           [\>]{.ul} 39 days            8.8                         16.6               
  SVZ dosimetric data                                                                                                  
  Ipsilateral dose                         \< 49.0 Gy (median)          8.7               0.251     16.9              0.618
                                           [\>]{.ul} 49.0 Gy (median)   9                           15.7               
                                           \< 40 Gy                     9.6               0.594     17.4              0.259
                                           [\>]{.ul} 40 Gy              8.7                         15.6               
                                           \< 59.4 Gy                   8.8               0.240     16.5              0.194
                                           [\>]{.ul} 59.4 Gy            10.1                        18.1               
  Contralateral dose                       \< 28.1 Gy (median)          9.4               0.981     17                0.569
                                           [\>]{.ul} 28.1 Gy (median)   8.4                         15.4               
                                           \< 40 Gy                     8.9               0.129     16.6              0.639
                                           [\>]{.ul} 40 Gy              9.7                         16.5               
                                           \< 59.4 Gy                   8.9               0.833     16.5              0.837
                                           [\>]{.ul} 59.4 Gy            11.5                        18.8               
  Bilateral dose                           \< 40.8 Gy (median)          9                 0.72      16.6              0.961
                                           [\>]{.ul} 40.8 Gy (median)   8.7                         16.5               
                                           \< 40 Gy                     8.8               0.277     16.4              0.645
                                           [\>]{.ul} 40 Gy              9                           16.9               
                                           \< 59.4 Gy                   8.9               0.862     16.5              0.312
                                           [\>]{.ul} 59.4 Gy            12.5                        16.9               
  SVZ dosimetric data from the GTR group                                                                               
  Ipsilateral dose                         \< 46.4 Gy (median)          9.4               0.707     17.7              0.590
                                           [\>]{.ul} 46.4 Gy (median)   9.8                         17                 
                                           \< 40 Gy                     9.5               0.770     19.1              0.576
                                           [\>]{.ul} 40 Gy              9.7                         17.1               
                                           \< 59.4 Gy                   9.5               0.225     17.2              0.567
                                           [\>]{.ul} 59.4 Gy            10.1                        18.1               
  Contralateral dose                       \< 23.4 Gy (median)          10.4              0.735     17.6              0.748
                                           [\>]{.ul} 23.4 Gy (median)   9.4                         17                 
                                           \< 40 Gy                     9.5               0.552     17.6              0.579
                                           [\>]{.ul} 40 Gy              9.7                         17                 
                                           \< 59.4 Gy                                     \-                          \-
                                           [\>]{.ul} 59.4 Gy                                                           
  Bilateral dose                           \< 34.9 Gy (median)          9.7               0.826     17.2              0.609
                                           [\>]{.ul} 34.9 Gy (median)   9.1                         17.8               
                                           \< 40 Gy                     9.3               0.222     17.2              0.823
                                           [\>]{.ul} 40 Gy              10.8                        17.5               
                                           \< 59.4 Gy                                     \-                          \-
                                           [\>]{.ul} 59.4 Gy                                                           
  ---------------------------------------- ---------------------------- ----------------- --------- ----------------- ---------
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For the multivariate analysis, stability of the model required the creation of different CPH models for each SVZ volume. Patients with multifocal tumors had significantly worse PFS, and patients with low KPS and minimal resection had significantly shorter OS (Table [4](#TAB4){ref-type="table"}).

###### Multivariate analysis.

\* Entered as a continuous variable.

SVZ: Subventricular zone; STR: Subtotal resection; GTR: Gross total resection.

  ---------------------------------------------- --------------------------- ------------ ------------------ --- ------ ------------ ---------
                                                 Progression-free Survival                Overall Survival                           
                                                 HR                          95% CI       P-value                HR     95% CI       P-value
  Ipsilateral SVZ                                                                                                                     
     Age ([\>]{.ul} 50 years vs. \< 50 years)    1.24                        0.95--1.63   0.11                   1.10   0.84--1.43   0.50
     Karnofsky score ([\<]{.ul} 70 vs. \> 70)    1.29                        0.98--1.69   0.07                   1.51   1.16--1.96   \<0.01
     Resection (STR vs. GTR)                     1.05                        0.81--1.36   0.70                   1.03   0.80--1.32   0.83
     Resection (biopsy vs. GTR)                  1.19                        0.83--1.71   0.33                   1.62   1.15--2.28   \<0.01
     Multifocality (yes vs. no)                  1.51                        1.11--2.04   \<0.01                 1.31   0.98--1.76   0.08
     Total dose ([\>]{.ul} 60 Gy vs. \< 60 Gy)   0.85                        0.59--1.22   0.37                   0.85   0.59--1.22   0.37
     Ipsilateral SVZ dose\*                      1.00                        0.99--1.01   0.70                   1.00   0.99--1.01   0.69
  ---------------------------------------------- --------------------------- ------------ ------------------ --- ------ ------------ ---------

Discussion
==========

This study found that for patients treated with long-course CRT, dose to the SVZ was not associated with PFS or OS. Furthermore, no benefit to increasing SVZ dose was observed when analysis was restricted to patients with GTR, a subgroup identified by a previous study as uniquely benefitting from high SVZ dose \[[@REF26]\].

Our results are contrary to prior studies that suggested higher dose to the SVZ improves outcome \[[@REF20], [@REF22]-[@REF26]\]. However, these studies were small, and used variable inclusion criteria. Some failed to address known prognostic factors such as performance status \[[@REF25]\] and adjuvant chemotherapy \[[@REF25], [@REF26]\]. Exclusion of multifocal tumors \[[@REF25], [@REF26]\] is also questionable, since multifocality is characteristic of stem-cell-derived tumors \[[@REF14], [@REF16]\] and often confers poor prognosis \[[@REF29]\]. It is worth noting that our findings are applicable to patients receiving combined radiation and temozolomide; thus, conclusions about the effectiveness of SVZ irradiation without concurrent chemotherapy cannot be made. Our study population is similar to others in terms of the incidental dose received by the SVZ. The mean dose received by the ipsilateral SVZ in our cohort was 47.8 Gy, which is very similar to Chen et al., at 49.2 Gy, and Lee et al., at 48.7 Gy. Due to the size of our study, our analysis had a larger group, n = 32, receiving a dose greater than 59.4 Gy. This is important because it allows for a more robust comparison with those receiving a lower dose. Indeed, Lee et al., which is the second largest study looking at this issue, had only 21 individuals in their high dose group.

Discrepancy exists among studies of SVZ irradiation. Although some demonstrate benefit \[[@REF20], [@REF22]-[@REF26]\], others have found no association between dose to the SVZ and outcome \[[@REF18]\], and one conversely suggested high SVZ dose was associated with worse prognosis \[[@REF17]\]. There is also disagreement within the positive studies as to which SVZ target volume may be associated with outcome (ipsilateral \[[@REF22], [@REF23], [@REF25], [@REF26]\], contralateral \[[@REF22]\], or bilateral \[[@REF24]\]).

The strengths of our study include its large size, with patients being treated at a single institution using a similar treatment protocol. Our study is limited by the retrospective nature of our data. We also employed very strict selection criteria, which has the potential to introduce selection bias. However, this was done to ensure our subjects would be comparable to those in prior studies of SVZ. Also, strict selection criteria were necessary to prevent further sources of bias. For example, subjects who did not complete radiotherapy were excluded; this was necessary, otherwise patients who deteriorated significantly during treatment would have inherently received a low SVZ dose, conceivably introducing further bias to the data. Chemotherapy compliance is potentially influenced by a number of factors (patient preference, toxicity, early tumor progression, etc.) which cannot be controlled in the retrospective setting, and although another important prognostic factor, it was not possible for this to be assessed. The most significant limitation of the present study is the lack of molecular marker data. It is well established that certain molecular features, such as IDH1 and MGMT status, can be prognostic and/or predictive of outcome \[[@REF19]\]. Unfortunately, during the time period when study population was treated the institution did not routinely obtain molecular marker data on patients with GBM. It is certainly possible that SVZ dose could potentially have differential effects in the setting of different molecular phenotypes.

Targeting stem cell reservoirs may not be clinically beneficial, and can lead to larger volumes of brain tissue receiving radiation dose. This is important because current phase II trials are deliberately including the SVZ in their target volume \[[@REF30]\]. The SVZ is anatomically close to the hippocampal formation, which is a structure important for memory and cognition that is being purposely avoided in studies using modern radiotherapy techniques \[[@REF27], [@REF28]\]. In the future, it would be worthwhile for similar studies to include tumor genetics in their analysis.

Conclusions
===========

The results of this study suggest that prognosis is unrelated to dose received by the SVZ. Indeed, prospective data are required to determine the value of SVZ irradiation in the treatment of GBM. However, trials deliberately including this region as a target volume should be done with caution.
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